By staff writers

October 23, 2019 -- BioGX announced that its new automated polymerase chain reaction (PCR) test for influenza A, influenza B, and respiratory syncytial virus (RSV) has received the CE-IVD Mark.

The company said it will gradually transition European customers to the new product.

The test is designed for use with Becton Dickinson's BD Max benchtop molecular diagnostic system, and it is suited for different collection methods, such as nasal wash, pharyngeal swab, and nasopharyngeal swab, according to the company. BioGX explained in a statement that it developed the test in response to customer demand for the ability to test a broader array of specimen samples.

Sekisui announces Acucy flu test clearance
Sekisui Diagnostics announced that its Acucy influenza A and B test has received 510(k) clearance and CLIA waiver from the U.S. Food and Drug Administration.
ELISA blood test helps identify flu immunity
Researchers used an enzyme-linked immunosorbent assay (ELISA) blood test to assess immune response in people exposed to the H1N1 influenza A virus and...
InDevR's flu assay gets green light from FDA
InDevR's FluChip-8G Influenza A+B assay -- designed to identify virus subtypes -- has received 510(k) marketing clearance from the U.S. Food and Drug...

Copyright © 2019

Last Updated np 10/22/2019 5:01:08 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.